Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms FavorAx
- 17 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2018.
- 17 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 11 Mar 2016 New trial record